…
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT at home for enhancement of physical functions. In addition, the company provides rescue support in disaster sites, and heavy labor support for factories and plants, as well as engages in the entertainment business. CYBERDYNE Inc. was incorporated in 2004 and is headquartered in Tsukuba, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cyberdyne Inc is a Japanese robotics and medical-device company known for its HAL exoskeleton used in rehabilitation, mobility support and care applications. Long-term growth may be supported by aging demographics, wider clinical adoption, overseas expansion and its specialized intellectual property, which could support scalable service and device revenue.
Principal risks include limited liquidity and disclosure as an OTC Pink ADR, reliance on regulatory approval and reimbursement, modest historical profitability and commercialization execution against competitive and technological challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | -879.00M | -1141.00M | 53.00M | -379.00M | 408.00M |
| Minority interest | 129.00M | 172.00M | 95.00M | 24.00M | 10.00M |
| Net income | -577.00M | -1476.00M | -298.00M | -492.00M | -59.00M |
| Selling general administrative | 2804.00M | 3251.00M | 2406.00M | 1787.00M | 1471.00M |
| Selling and marketing expenses | - | 656.00M | 271.00M | 169.00M | - |
| Gross profit | 2373.00M | 2393.00M | 1791.00M | 1462.00M | 1284.00M |
| Reconciled depreciation | 592.00M | 677.00M | 627.00M | 473.00M | 463.00M |
| Ebit | -576.00M | -659.00M | -28.00M | -490.00M | 51.00M |
| Ebitda | 16.00M | 18.00M | 599.00M | -17.00M | 514.00M |
| Depreciation and amortization | 592.00M | 677.00M | 627.00M | 473.00M | 463.00M |
| Operating income | -926.00M | -2018.00M | -1145.00M | -868.00M | -700.00M |
| Other operating expenses | 5310.00M | 6372.00M | 4435.00M | 3019.00M | 2574.00M |
| Interest expense | 303.00M | 482.00M | 193.00M | 4.00M | 2.00M |
| Tax provision | -174.00M | 507.00M | 446.00M | 136.00M | 479.00M |
| Interest income | 539.00M | 543.00M | 1312.00M | 398.00M | 770.00M |
| Net interest income | 236.00M | 61.00M | 1119.00M | 394.00M | 768.00M |
| Income tax expense | -174.00M | 507.00M | 446.00M | 136.00M | 479.00M |
| Total revenue | 4384.00M | 4354.00M | 3289.00M | 2150.00M | 1875.00M |
| Total operating expenses | 3299.00M | 4411.00M | 2937.00M | 2331.00M | 1983.00M |
| Cost of revenue | 2011.00M | 1961.00M | 1498.00M | 688.00M | 591.00M |
| Total other income expense net | 47.00M | 877.00M | 1296.00M | 575.00M | 1149.00M |
| Net income from continuing ops | -705.00M | -1648.00M | -393.00M | -515.00M | -71.00M |
| Net income applicable to common shares | - | - | - | -492.00M | -59.00M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 48547.00M | 49999.00M | 50187.00M | 49459.00M | 48119.00M |
| Intangible assets | 45.00M | 48.00M | 80.00M | 35.00M | 38.00M |
| Other current assets | 178.00M | 139.00M | 308.00M | 455.00M | 349.00M |
| Total liab | 8954.00M | 9522.00M | 8204.00M | 6002.00M | 4333.00M |
| Total stockholder equity | 39575.00M | 40752.00M | 42101.00M | 43419.00M | 43776.00M |
| Other current liab | 384.00M | 386.00M | 365.00M | 376.00M | 275.00M |
| Common stock | 10.00M | 10.00M | 10.00M | 10.00M | 10.00M |
| Capital stock | 10.00M | 10.00M | 10.00M | 10.00M | 10.00M |
| Retained earnings | -801.00M | -95.00M | 1381.00M | 1685.00M | 2177.00M |
| Other liab | - | - | 6480.00M | 4751.00M | 3369.00M |
| Good will | 1766.00M | 2134.00M | 2531.00M | 2104.00M | 57.00M |
| Other assets | -1.00M | - | 13807.00M | -1.00M | 1.00M |
| Cash | 6824.00M | 5155.00M | 7801.00M | 5677.00M | 6704.00M |
| Total current liabilities | 1085.00M | 1236.00M | 1291.00M | 828.00M | 635.00M |
| Current deferred revenue | - | 1.00M | - | - | - |
| Net debt | -6390.00M | -4523.00M | -7132.00M | -5102.00M | -6283.00M |
| Short term debt | 168.00M | 244.00M | 236.00M | 152.00M | 92.00M |
| Short long term debt | 22.00M | 84.00M | 89.00M | 34.00M | 31.00M |
| Short long term debt total | 434.00M | 632.00M | 669.00M | 575.00M | 421.00M |
| Other stockholder equity | 41109.00M | 41623.00M | -1391.00M | -1695.00M | -2187.00M |
| Property plant equipment | - | - | 14382.00M | 14345.00M | 13018.00M |
| Total current assets | 16758.00M | 18469.00M | 19147.00M | 22865.00M | 27220.00M |
| Net tangible assets | - | - | - | 41280.00M | 43681.00M |
| Short term investments | 8033.00M | 11504.00M | 9507.00M | 15151.00M | 19007.00M |
| Net receivables | 800.00M | 674.00M | 540.00M | 493.00M | 352.00M |
| Long term debt | 15.00M | 22.00M | 21.00M | 34.00M | 49.00M |
| Inventory | 923.00M | 997.00M | 991.00M | 1089.00M | 808.00M |
| Accounts payable | 533.00M | 606.00M | 690.00M | 300.00M | 268.00M |
| Accumulated other comprehensive income | -743.00M | -786.00M | - | - | - |
| Non currrent assets other | 15835.00M | 195.00M | 166.00M | 104.00M | 60.00M |
| Non current assets total | 31790.00M | 31530.00M | 31040.00M | 26594.00M | 20898.00M |
| Capital lease obligations | 397.00M | 526.00M | 559.00M | 507.00M | 341.00M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | 2325.00M | -2075.00M | 2173.00M | 2153.00M | -1715.00M |
| Change to liabilities | - | - | 0.00M | -76.00M | 45.00M |
| Total cashflows from investing activities | 2325.00M | -2075.00M | - | -1788.00M | -2794.00M |
| Net borrowings | -5.00M | -10.00M | -165.00M | -47.00M | -9.00M |
| Total cash from financing activities | -216.00M | 160.00M | 14.00M | 1248.00M | 617.00M |
| Change to operating activities | - | - | - | 87.00M | -788.00M |
| Net income | -879.00M | -1476.00M | 53.00M | -379.00M | 408.00M |
| Change in cash | 1669.00M | -2646.00M | 2124.00M | -1027.00M | -2932.00M |
| Begin period cash flow | 5155.00M | 7801.00M | 5677.00M | 6704.00M | 9636.00M |
| End period cash flow | 6824.00M | 5155.00M | 7801.00M | 5677.00M | 6704.00M |
| Total cash from operating activities | -430.00M | -850.00M | -143.00M | -564.00M | -775.00M |
| Depreciation | 592.00M | 677.00M | 627.00M | 473.00M | 463.00M |
| Other cashflows from investing activities | 1.00M | 24.00M | - | -18.00M | -4.00M |
| Change to inventory | 74.00M | -6.00M | 98.00M | -281.00M | 24.00M |
| Change to account receivables | -126.00M | -134.00M | -275.00M | 29.00M | -88.00M |
| Sale purchase of stock | 0.00M | 0.00M | -1188.00M | -1188.00M | - |
| Other cashflows from financing activities | -211.00M | 170.00M | 1214.00M | 1295.00M | 646.00M |
| Change to netincome | - | - | -674.00M | -417.00M | -839.00M |
| Capital expenditures | 305.00M | 224.00M | 509.00M | 1776.00M | 1075.00M |
| Change in working capital | -125.00M | -848.00M | 202.00M | -328.00M | -19.00M |
| Other non cash items | -18.00M | 797.00M | -1025.00M | -330.00M | -1627.00M |
| Free cash flow | -735.00M | -1074.00M | -652.00M | -2340.00M | -1850.00M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CYBQY Cyberdyne Inc ADR |
0.05 4.63% |
1.13 | - | 250.00 | 0.09 | 1.50 | 13.10 | 88.01 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT at home for enhancement of physical functions. In addition, the company provides rescue support in disaster sites, and heavy labor support for factories and plants, as well as engages in the entertainment business. CYBERDYNE Inc. was incorporated in 2004 and is headquartered in Tsukuba, Japan.
| Name | Title | Year Born |
|---|---|---|
| Mr. Yoshiyuki Sankai | Chairman, Pres & CEO | 1958 |
| Mr. Shinji Uga | Head of Corp. Unit & Director | 1970 |
| Dr. Yoshiyuki Sankai | Chairman, President & CEO | 1958 |
| Mr. Shinji Honda | Executive Director & COO | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.